Kiora Pharmaceuticals, Inc.
KPRXHealthcare|Biotechnology|US
$1.44
-0.06 (-4.00%)
DCF Value
$2.55
Tangible Book / Share
$2.39
Cash / Share
$2.73
Clinical Trials (5)
| Trial | Conditions | Phase | Status | Enrollment | Design | Drug |
|---|---|---|---|---|---|---|
| NCT06628947 A Phase II Study of Intravitreal KIO-301 in Patients With Late-stage Retinitis Pigmentosa | Retinitis Pigmentosa | P2 | Recruiting | 36 | RCT, Double-blind | 100 μg KIO-301, 50 μg KIO-301 |
| NCT06825702 Safety, Tolerability and Efficacy of Intravitreal KIO-104 in Patients With Macular Edema | Macular Edema | P2 | Recruiting | 28 | Open-label | KIO-104 |
| NCT05436288 A Study of the KIO-201 (Ocular Bandage Gel) for Improving Persistent Corneal Epithelial Defects | Persistent Corneal Epithelial Defect | P2 | Completed | 10 | Open-label | KIO-201, a Crosslinked Thiolated Carboxymethyl Hyaluronic Acid 0.75% (CMHA-S) |
| NCT05282953 A Phase I/II Dose-escalating Study of the Safety, Tolerability and Efficacy of KIO-301 Administered Intravitreally to Patients With Retinitis Pigmentosa and Choroideremia (ABACUS) | Retinitis Pigmentosa, Choroideremia | P1P2 | Completed | 32 | Open-label | KIO-301 |
| NCT05629364 A Multi-Centre, Randomised, Controlled, Masked Phase 2 Study of the Safety and Efficacy of KIO-101 Ophthalmic Solution, Versus Vehicle Control in the Treatment of Dry Eye Disease in Patients With Autoimmune Disease | Dry Eye Disease | P2 | Terminated | 4 | RCT, Double-blind | KIO-101 |